MarketBeat · 14 Aug 2026positive
At the Canaccord Genuity Growth Conference, Guardant Health's co-CEOs highlighted growth across its oncology testing, minimal residual disease, and colorectal cancer screening businesses, citing expanding adoption, new reimbursement developments, and planned product launches.
Why it matters — GH watchers would care because management detailed growth drivers and upcoming reimbursement and product developments across its three main testing segments.
Seeking Alpha · 12 Aug 2026neutral
Guardant Health, Inc. presented at Canaccord Genuity's 46th Annual Growth Conference, and a transcript of the presentation was published by Seeking Alpha. The presentation represents the company's participation in a major investor growth conference.
Why it matters — A GH watcher would care because the presentation transcript offers insight into the company's public remarks and strategy discussion delivered to investors at the conference.
Seeking Alpha · 11 Aug 2026positive
Guardant Health is experiencing robust growth driven by its MRD and screening businesses. Recent FDA approvals, expanded reimbursement, and inclusion in clinical guidelines should help sustain that growth, though competition in both screening and MRD monitoring is set to intensify in coming years.
Why it matters — A GH watcher would care because FDA approvals, expanded reimbursement, and guideline inclusion signal the drivers behind the company's current growth, alongside the competitive pressures expected ahead.
Business Wire · 10 Aug 2026neutral
Guardant Health announced that on July 21, 2026, its Compensation Committee approved granting restricted stock units totaling 46,044 shares of common stock to 149 new non-executive employees, with a grant date of August 3, 2026, under the company's 2023 Employment Inducement Incentive Award Plan.
Why it matters — The grants, made as hiring inducements under Nasdaq Listing Rule 5635(c)(4), signal ongoing employee recruitment and equity compensation activities for GH watchers to note.
Seeking Alpha · 6 Aug 2026positive
In its Q2 2026 portfolio review, Alger Small Cap Focus Fund cited Guardant Health, Inc. as one of the top contributors to fund performance during the quarter, alongside Nebius Group and Credo Technology Group. The report also identified Karman Holdings, GeneDx Holdings, and Forte Biosciences as top detractors.
Why it matters — GH watchers would note that a major small-cap fund highlighted Guardant Health as a top performer, signaling positive fund-manager recognition of the stock's quarterly contribution.
